Consistent with this conclusion, administration of the Th1 cytokines IL-12 and IFN-γ can induce lesional regression associated with increased numbers of cytotoxic CD8+ T cells in the resolving skin, and treatment with Toll-like receptor (TLR) agonists that stimulate cellular immunity have shown clinical efficacy in CTCL patients [136–144]. The gene discussed is IFNG; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.